Your browser is no longer supported. Please, upgrade your browser.
MDGL Madrigal Pharmaceuticals, Inc. daily Stock Chart
Madrigal Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.45 Insider Own10.80% Shs Outstand15.55M Perf Week-12.51%
Market Cap935.02M Forward P/E- EPS next Y-11.48 Insider Trans-59.14% Shs Float13.76M Perf Month-34.01%
Income-83.90M PEG- EPS next Q-1.95 Inst Own97.60% Short Float17.80% Perf Quarter-30.87%
Sales- P/S- EPS this Y-145.90% Inst Trans0.10% Short Ratio13.34 Perf Half Y-30.06%
Book/sh27.00 P/B2.23 EPS next Y-30.50% ROA-18.20% Target Price179.83 Perf Year-55.37%
Cash/sh28.23 P/C2.13 EPS next 5Y0.00% ROE-18.80% 52W Range56.82 - 145.16 Perf YTD-34.00%
Dividend- P/FCF- EPS past 5Y29.20% ROI- 52W High-58.58% Beta1.14
Dividend %- Quick Ratio17.50 Sales past 5Y- Gross Margin- 52W Low5.83% ATR6.15
Employees29 Current Ratio17.50 Sales Q/Q- Oper. Margin- RSI (14)29.43 Volatility7.90% 9.27%
OptionableYes Debt/Eq0.00 EPS Q/Q-140.60% Profit Margin- Rel Volume1.08 Prev Close60.59
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 Payout- Avg Volume183.63K Price60.13
Recom2.00 SMA20-17.61% SMA50-26.15% SMA200-34.34% Volume199,118 Change-0.76%
Jan-30-20Initiated Canaccord Genuity Buy $198
Jan-09-20Upgrade UBS Neutral → Buy $125 → $127
Nov-07-19Reiterated H.C. Wainwright Buy $225 → $215
Jun-25-19Initiated Stifel Hold
Jun-10-19Upgrade B. Riley FBR Neutral → Buy $128
Feb-28-19Reiterated H.C. Wainwright Buy $313 → $228
Feb-22-19Initiated SVB Leerink Outperform $165
Jan-23-19Initiated UBS Neutral $119
Dec-14-18Initiated Wolfe Research Outperform
Dec-12-18Initiated B. Riley FBR Neutral $124
Nov-19-18Downgrade Raymond James Mkt Perform → Underperform
Nov-16-18Upgrade Evercore ISI In-line → Outperform
Sep-04-18Initiated Citigroup Buy $340
Aug-06-18Downgrade Goldman Buy → Neutral
Jun-28-18Initiated Raymond James Mkt Perform
Jun-19-18Downgrade Evercore ISI Outperform → In-line
Jun-01-18Upgrade Oppenheimer Perform → Outperform
Jun-01-18Reiterated ROTH Capital Buy $210 → $400
Jun-01-18Reiterated H.C. Wainwright Buy $178 → $313
Mar-23-18Initiated Goldman Buy $191
Mar-30-20 06:06PM  FDA Decisions on 5 Drugs Expected in 2nd Quarter
Feb-28-20 10:49AM  What Kind Of Share Price Volatility Should You Expect For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)? Simply Wall St.
Feb-26-20 06:50AM  Madrigal Pharmaceuticals Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights GlobeNewswire
Feb-05-20 04:11PM  13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market Benzinga
Jan-21-20 01:27PM  Is It Time to Buy These 3 Beaten-Down Stocks? Analysts Say Yes TipRanks
Dec-19-19 07:28PM  Madrigal Pharmaceuticals, Inc. (MDGL): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-18-19 06:50AM  Madrigal Pharmaceuticals Announces First Patient Dosed in MAESTRO-NAFLD-1, a Second Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Resmetirom (MGL-3196) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Presumed NASH (NASH/NAFLD (non-alcoholic fatty liver disease)) GlobeNewswire
Dec-13-19 06:20AM  Madrigal Pharmaceuticals investor selling large chunk of its stake American City Business Journals
Dec-10-19 11:58PM  Madrigal Pharmaceuticals Announces Pricing of Secondary Offering GlobeNewswire
04:01PM  Madrigal Pharmaceuticals Announces Secondary Offering of 1,200,000 Shares of Common Stock GlobeNewswire
Nov-29-19 08:41AM  NASH Scorecard Year to Date: The Winners and the Losers Zacks
Nov-11-19 05:30PM  Madrigal Pharmaceuticals Announces Publication in The Lancet of Positive Phase 2 Results for Resmetirom (MGL-3196) for the Treatment of Non-alcoholic Steatohepatitis (NASH) GlobeNewswire
Nov-06-19 06:50AM  Madrigal Pharmaceuticals Reports 2019 Third Quarter Financial Results and Highlights GlobeNewswire
Oct-26-19 01:22PM  Hedge Funds Are Dumping Madrigal Pharmaceuticals, Inc. (MDGL) Insider Monkey
Sep-19-19 03:28PM  What Kind Of Share Price Volatility Should You Expect For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)? Simply Wall St.
Aug-07-19 06:50AM  Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights GlobeNewswire
Jul-11-19 06:50AM  Madrigal Pharmaceuticals Promotes Rebecca Taub, M.D., Chief Medical Officer and Executive Vice President of Research & Development, to Newly Created Position of President of Research & Development GlobeNewswire
Jul-10-19 01:26PM  Have Insiders Been Buying Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares? Simply Wall St.
Jul-02-19 06:50AM  Madrigal Pharmaceuticals Announces Appointment of Jim Daly to Board of Directors GlobeNewswire
Jun-19-19 09:07PM  Heres What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL) Insider Monkey
Jun-07-19 01:29PM  2 Falling Knives With No Debt
Jun-04-19 06:50AM  Madrigal Pharmaceuticals to Present at Upcoming Investment Conferences GlobeNewswire
May-15-19 04:42PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of Madrigal Pharmaceuticals, Inc. GlobeNewswire
May-08-19 10:14AM  If You Had Bought Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock A Year Ago, You'd Be Sitting On A 12% Loss, Today Simply Wall St.
06:56AM  Madrigal: 1Q Earnings Snapshot Associated Press
06:50AM  Madrigal Pharmaceuticals Reports 2019 First Quarter Financial Results and Highlights GlobeNewswire
May-01-19 12:49PM  Is Madrigal Pharmaceuticals, Inc. (MDGL) A Good Stock To Buy? Insider Monkey
Apr-08-19 06:50AM  Madrigal Pharmaceuticals to Present Additional Analyses of Data from The Phase 2 NASH Study with MGL-3196 (resmetirom) at The International Liver Congress 2019 GlobeNewswire
Apr-06-19 08:03AM  Here's Why Investors Are Betting Against These 2 Biotech Stocks Motley Fool
Mar-28-19 06:50AM  Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation GlobeNewswire
Mar-01-19 11:49AM  Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus Zacks +7.09%
Feb-27-19 01:25PM  Is Viking Therapeutics a Buy? Motley Fool
10:39AM  All You Need To Know About Madrigal Pharmaceuticals, Inc.s (NASDAQ:MDGL) Financial Health Simply Wall St.
06:50AM  Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights GlobeNewswire
Feb-20-19 08:11AM  Intercept Reports Positive Top-Line Data for NASH, Shares Up Zacks -8.39%
Feb-17-19 02:03PM  Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals Motley Fool
Feb-12-19 04:20PM  Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails Zacks
Jan-11-19 08:59AM  Here's Why Viking Therapeutics Slid 32.2% in December Motley Fool
Jan-08-19 05:13PM  Here's Why Viking Therapeutics Skyrocketed 88.4% in 2018 Motley Fool
Dec-28-18 04:52PM  Intercept (ICPT) Benefits from Ocaliva's Recovery in 2018 Zacks
Dec-12-18 11:03PM  Here is What Hedge Funds Think About Madrigal Pharmaceuticals, Inc. (MDGL) Insider Monkey
08:19AM  3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019 Motley Fool
Dec-08-18 03:03PM  Here's Why Madrigal Pharmaceuticals Fell 39.4% in November Motley Fool
Nov-28-18 08:40AM  Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-23-18 09:15PM  Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $471,520 of Shares
Nov-19-18 08:15PM  Madrigal Pharmaceuticals Inc (MDGL) CEO Paul A Friedman Bought $496,000 of Shares -7.26%
02:57PM  Viking Has A More Attractive M&A Valuation Than Madrigal, Raymond James Says In Upgrade Benzinga
Nov-14-18 08:31AM  Better NASH Stock: Madrigal Pharmaceuticals, Inc. vs. Viking Therapeutics, Inc. Motley Fool
Nov-12-18 03:37PM  Madrigal preparing for late-stage testing of experimental NASH treatment American City Business Journals
11:30AM  Phase 2 Results for Madrigals MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018 GlobeNewswire
09:00AM  Why Madrigal Pharmaceuticals Stock Slumped in October Motley Fool
Nov-06-18 06:50AM  Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events GlobeNewswire
Oct-27-18 07:18AM  Better Buy: Intercept Pharmaceuticals Inc. vs. Madrigal Pharmaceuticals Motley Fool
Oct-19-18 08:15AM  Research Report Identifies Brookfield Asset Management, Becton, Dickinson, IPG Photonics, ASML Holding N.V, American National Insurance, and Madrigal Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Sep-26-18 03:21PM  5 Biotech Stocks to Play the Sectors Next Big Trend: NASH InvestorPlace
Sep-20-18 08:48AM  Is Viking Therapeutics the Best NASH Stock to Buy Now? Motley Fool
Sep-19-18 08:00AM  Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Cara Therapeutics ACCESSWIRE
Sep-18-18 03:00PM  Viking Therapeutics and Madrigal Pharmaceuticals Are Racing to the Finish Line in NASH Motley Fool -9.25%
10:00AM  Why Viking Therapeutics Stock Is Soaring Today Motley Fool
08:14AM  UPDATE: Viking Therapeutics stock rockets 140% after positive trial of non-alcoholic fatty liver treatment MarketWatch
Sep-12-18 09:17AM  3 Top Stocks for Investing in Pharma's Next $35 Billion Market Motley Fool
Aug-19-18 09:02AM  Is Viking Therapeutics, Inc. a Buy? Motley Fool
Aug-07-18 10:22AM  Madrigal (MDGL) Posts Narrower than Expected Loss in Q2 Zacks
06:50AM  Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements GlobeNewswire
Aug-06-18 03:05PM  Goldman Sachs Cuts Madrigal Pharma To Neutral Given No Near-Term Catalysts Benzinga
Jul-30-18 02:39PM  Why Madrigal Pharmaceuticals Stock Is Getting Hammered Today Motley Fool -5.76%
Jul-26-18 01:33PM  How a little 10-employee pharma company hit a whopping $4.4B market cap American City Business Journals
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-14-18 07:16AM  The 4 Best Biotech Stocks of 2018 (So Far) Motley Fool
Jul-11-18 09:15AM  3 Huge Biotech Winners in 2018 (So Far) Motley Fool
Jul-03-18 08:10AM  Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Zuora ACCESSWIRE
Jul-02-18 03:23PM  Best ETFs for 2018: ALPS Medical Breakthroughs ETF Keeps Rolling Along InvestorPlace +5.83%
Jun-26-18 11:27AM  Viking Therapeutics, Buy the Dip? Motley Fool
07:06AM  This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-23-18 10:21AM  Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives Benzinga
Jun-18-18 11:45AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-15-18 02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool
10:26AM  MARKETS: Here's why stocks are dropping right now Yahoo Finance Video
Jun-14-18 10:30AM  Are These Red-Hot NASH Stocks Still a Buy? Motley Fool
Jun-13-18 11:23AM  Madrigal Pharma Is Exploring Sale After Receiving Takeover Interest Bloomberg +10.80%
Jun-06-18 11:14PM  Madrigal Pharmaceuticals Prices Public Offering of Common Stock GlobeNewswire
Jun-05-18 04:10PM  Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire +10.17%
Jun-04-18 09:44AM  Company News For Jun 4, 2018 Zacks
07:40AM  Wired News - Madrigal Pharma Reported Encouraging Top-line Data at 36 Weeks from Phase-2 Clinical Trial of MGL-3196 in Patients with NASH ACCESSWIRE
Jun-03-18 11:35AM  Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy MarketWatch
Jun-02-18 04:10PM  Maxim Explains Viking Therapeutics' Sympathy Move With Madrigal Benzinga
07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-01-18 08:16AM  Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO Benzinga
08:10AM  Todays Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and Viking Therapeutics ACCESSWIRE
05:10AM  Viking Therapeutics Breaks Out to Key Resistance Levels Investopedia
May-31-18 04:34PM  Why Madrigal Pharmaceuticals, Brink's, and Applied Optoelectronics Jumped Today Motley Fool +144.96%
04:15PM  145% climb: Madrigal Pharmaceuticals' stock soars on positive study results American City Business Journals
04:02PM  Madrigal Pharma Shares Double After Successful Phase II Results For Fatty Liver Drug Forbes
12:27PM  Why Viking Therapeutics Stock Is On Fire Today Motley Fool
11:27AM  Here's Why Madrigal Pharmaceuticals Is Skyrocketing Today Motley Fool
08:49AM  Madrigal Threatens Intercept's Lead in Fatty Liver Disease Bloomberg
08:27AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:50AM  Madrigals MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial GlobeNewswire
May-29-18 12:13PM  Pharma Companies Race to Find Wonder Drug for Obesity-Linked Liver Disease Bloomberg
07:40AM  Report: Exploring Fundamental Drivers Behind Vivint Solar, Peapack-Gladstone Financial, Madrigal Pharmaceuticals, Univest Corporation of Pennsylvania, Amtech, and Lithia Motors New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAY CITY CAPITAL LLC10% OwnerDec 13Sale105.471,200,000126,564,00088,152Dec 13 02:18 PM
CRAVES FRED BDirectorDec 13Sale105.471,200,000126,564,00088,152Dec 13 02:08 PM